Global Fractional Flow Reserve Value Predicts 5-Year Outcomes in Patients With Coronary Atherosclerosis But Without Ischemia.
Aged
Atherosclerosis
/ complications
Cardiovascular Diseases
/ epidemiology
Case-Control Studies
Cause of Death
/ trends
Coronary Angiography
/ methods
Coronary Artery Disease
/ physiopathology
Coronary Vessels
/ diagnostic imaging
Cost of Illness
Female
Follow-Up Studies
Fractional Flow Reserve, Myocardial
/ physiology
Humans
Male
Middle Aged
Myocardial Infarction
/ epidemiology
Myocardial Revascularization
/ statistics & numerical data
Percutaneous Coronary Intervention
/ methods
Predictive Value of Tests
Prognosis
Prospective Studies
Risk Assessment
Time Factors
coronary atherosclerosis
fractional flow reserve
percutaneous coronary intervention
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
15 12 2020
15 12 2020
Historique:
pubmed:
8
12
2020
medline:
17
3
2021
entrez:
7
12
2020
Statut:
ppublish
Résumé
Background Global fractional flow reserve (FFR) (ie, the sum of the FFR values in the 3 major coronary arteries) is a physiologic correlate of global atherosclerotic burden. The objective of the present study was to investigate the value of global FFR in predicting long-term clinical outcome of patients with stable coronary artery disease but no ischemia-inducing stenosis. Methods and Results We studied major adverse cardiovascular events (MACEs: all-cause death, myocardial infarction, and any revascularization) after 5 years in 1122 patients without significant stenosis (all FFR >0.80; n=275) or with at least 1 significant stenosis successfully treated by percutaneous coronary intervention (ie, post-percutaneous coronary intervention FFR >0.80; n=847). The patients were stratified into low, mid, or high tertiles of global FFR (≤2.80, 2.80-2.88, and ≥2.88). Patients in the lowest tertile of global FFR showed the highest 5-year MACE rate compared with those in the mid or high tertile of global FFR (27.5% versus 22.0% and 20.9%, respectively; log-rank
Identifiants
pubmed: 33283600
doi: 10.1161/JAHA.120.017729
pmc: PMC7955380
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e017729Références
JACC Cardiovasc Imaging. 2015 Oct;8(10):1209-22
pubmed: 26481846
J Am Heart Assoc. 2020 Dec 15;9(24):e017729
pubmed: 33283600
Eur Heart J. 2011 Jun;32(11):1316-30
pubmed: 21367834
J Am Coll Cardiol. 2016 Nov 29;68(21):2247-2255
pubmed: 27884241
J Am Coll Cardiol. 2018 Feb 6;71(5):499-509
pubmed: 29406855
J Am Coll Cardiol. 2011 Aug 16;58(8):849-60
pubmed: 21835321
N Engl J Med. 2009 Jan 15;360(3):213-24
pubmed: 19144937
Eur Heart J. 2012 Mar;33(6):734-44
pubmed: 21911339
N Engl J Med. 2014 Sep 25;371(13):1208-17
pubmed: 25176289
N Engl J Med. 2011 Jan 20;364(3):226-35
pubmed: 21247313
Circulation. 2001 Nov 13;104(20):2401-6
pubmed: 11705815
Circ Cardiovasc Imaging. 2015 Feb;8(2):e002332
pubmed: 25666717
Eur Heart J. 2018 Mar 14;39(11):945-951
pubmed: 29020260
N Engl J Med. 2012 Sep 13;367(11):991-1001
pubmed: 22924638
J Am Coll Cardiol. 2013 Jan 22;61(3):388
pubmed: 23328616
Circ Cardiovasc Imaging. 2014 Mar;7(2):282-91
pubmed: 24550435
Lancet. 2015 Nov 7;386(10006):1853-60
pubmed: 26333474
Circulation. 2000 Apr 25;101(16):1931-9
pubmed: 10779459
Heart. 2016 Oct 15;102(20):1655-61
pubmed: 27302987
JACC Cardiovasc Imaging. 2020 Mar;13(3):746-756
pubmed: 31422133
J Am Coll Cardiol. 2014 Oct 21;64(16):1641-54
pubmed: 25323250
Eur Heart J. 2014 Oct 21;35(40):2831-8
pubmed: 24644308
J Am Coll Cardiol. 2018 Jun 19;71(24):2756-2769
pubmed: 29802016
J Am Coll Cardiol. 2010 Jul 13;56(3):177-84
pubmed: 20537493
Circ Cardiovasc Interv. 2017 Aug;10(8):
pubmed: 28790165
Circulation. 2019 Jan 22;139(4):477-484
pubmed: 30586699